Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Study Evaluating Licaminlimab for Dry Eye Disease
Sponsor: Oculis
Summary
The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.
Official title: A Phase 2b/3, Double-masked, Randomized, Vehicle-controlled, Multicenter Study Evaluating Licaminlimab in Dry Eye Disease Patients With a Specific TNFR1 Genotype
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2026-04-16
Completion Date
2026-12
Last Updated
2026-04-24
Healthy Volunteers
No
Conditions
Interventions
Artificial Tear Run-in
Artificial tear eye drop run-in three times daily (TID) for approximately 14 days.
licaminlimab
Licaminlimab eye drops three times daily (TID) for 29 days.
Vehicle of licaminlimab
Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days.
Locations (10)
Global Research Management
Glendale, California, United States
Eye Research Foundation
Newport Beach, California, United States
Vision Institute
Colorado Springs, Colorado, United States
Segal Drug Trials, Inc.
Delray Beach, Florida, United States
Oculus Research, Inc.
Garner, North Carolina, United States
CORE, Inc
Shelby, North Carolina, United States
Scott & Christie and Associates
Cranberry Township, Pennsylvania, United States
Erie Retina Research
Erie, Pennsylvania, United States
Total Eye Care, PA
Memphis, Tennessee, United States
Piedmont Eye Center, Inc.
Lynchburg, Virginia, United States